Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

• المؤلفون الرئيسيون: Pianko S., Zeuzem S., Chuang WL., Foster GR., Sarin SK., Flisiak R., Lee CM., Andreone P., Piratvisuth T., Shah S., Sood A., George J., Gould M., Komolmit P., Thongsawat S., Tanwandee T., Rasenack J., Li Y., Pang M., Yin Y., Feutren G., Jacobson IM., for the B2202 Study Team.
• التنسيق: مقال
• اللغة: English
• منشور في: 2014
• الوصول للمادة أونلاين: http://www.ncbi.nlm.nih.gov/pubmed/22863266; http://cmuir.cmu.ac.th/handle/6653943832/4001
• المؤسسة: Chiang Mai University

Summary. Albinterferon alfa-2b (albIFN) is a fusion protein of recombinant human albumin/recombinant interferon (IFN)-α-2b, with ∼200-h half-life. Safety/efficacy of albIFN q4wk was evaluated in 391 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 2/3. Patients were randomized...